United States Plasma-Derived Therapeutics Market to hit US$ 10.53 Billion by 2033 | Major Companies 2026 - Takeda Pharmaceutical Company Limited, Johnson & Johnson, Octapharma AG

Leander, Texas and Tokyo, Japan - Jan.13.2026
As per DataM intelligence research report "The global plasma-derived therapeutics market was valued at US$ 20.16 Billion in 2023. The market size reached US$ 21.26 Billion in 2024 and is expected to reach US$ 35.10 Billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033."

The plasma-derived therapeutics market is expanding due to advancements in purification technologies and biologics manufacturing. Innovative fractionation processes and recombinant solutions improve treatment efficiency and patient safety. Growing demand for immunoglobulins and clotting factor therapies is fueling global market growth.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/plasma-derived-therapeutics-market?prasad

Plasma-Derived Therapeutics Market: Competitive Intelligence
Takeda Pharmaceutical Company Limited, Johnson and Johnson (DePuy Synthes), Octapharma AG, Arthrex, Inc., Grifols, S.A., ADMA Biologics

In the Plasma‐Derived Therapeutics Market, the combined strength of Takeda Pharmaceutical Company Limited, Johnson & Johnson (DePuy Synthes), Octapharma AG, Arthrex, Inc., Grifols, S.A., ADMA Biologics, Inc., CSL, Evolve Biologics Inc., Kamada Pharmaceuticals, and Bio Products Laboratory Ltd. underscores a deep commitment to delivering critical, life‐saving plasma‐derived medicines that address immune deficiencies, bleeding disorders, and other serious conditions. These companies advance the market by scaling the collection, fractionation, and formulation of human plasma into high‐value therapeutics such as immunoglobulins, clotting factors, and albumin, supporting both acute and chronic patient needs worldwide. Their investments in robust quality systems and regulatory compliance enhance product safety and reliability, strengthening clinician confidence and patient access. Through broad global distribution networks and strategic partnerships, they help ensure stable supply chains that mitigate regional shortages and rising demand pressures. Collectively, they reinforce the Plasma‐Derived Therapeutics Market as an indispensable pillar of modern treatment paradigms across immunology and hematology.

Individually and in synergy, these organizations' capabilities amplify innovation and competitive differentiation within the Plasma‐Derived Therapeutics Market by bringing complementary expertise in biologics development, clinical evidence generation, and therapeutic specialization. Takeda and Grifols combine extensive plasma infrastructure with diversified pipelines that support a wide range of indications, enhancing market depth. Octapharma AG and CSL leverage advanced fractionation technologies and formulation know‐how to deliver high‐potency, well‐tolerated products that meet global clinical standards. ADMA Biologics and Kamada Pharmaceuticals focus on specialized immune therapies that expand treatment options for under‐served patient populations. Evolve Biologics Inc. and Bio Products Laboratory Ltd. contribute agile development approaches and targeted portfolios that address niche therapeutic needs, while Johnson & Johnson's DePuy Synthes unit complements plasma‐derived treatments with related biologic and medical device ecosystems. Together, these strengths create a resilient innovation pipeline and a diversified product landscape that propel sustained growth in the Plasma‐Derived Therapeutics Market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/plasma-derived-therapeutics-market?prasad

United States: Recent Industry Developments

✅ In January 2026, CSL Behring introduced automated platforms for plasma-derived therapeutics production, integrating robotics, AI quality monitoring, and automated purification systems to improve batch consistency, safety, and yield across manufacturing lines.

✅ In November 2025, Grifols invested $120 million to expand automated plasma fractionation and purification, using AI-assisted monitoring and robotics to optimize process efficiency and product quality.

✅ In August 2025, startups deployed AI-driven plasma therapeutic platforms for automated monitoring, fractionation, and real-time quality analytics, reducing errors and improving scalability.

✅ In June 2025, U.S. plasma centers implemented robotic-assisted processing systems with automated pathogen screening and fractionation to improve safety, efficiency, and reproducibility in therapeutic production.

Japan: Recent Industry Developments

✅ In January 2026, Japanese firms launched automated plasma-derived therapeutic systems with AI-assisted quality control, supported by $50 million investment, optimizing fractionation, pathogen screening, and batch consistency to meet clinical demand.

✅ In October 2025, Takeda and Mitsubishi developed robotic-assisted plasma purification systems integrating real-time monitoring, automated pathogen detection, and AI analytics for enhanced therapeutic production.

✅ In July 2025, research institutes piloted automated plasma fractionation platforms, using robotics and AI to standardize production and reduce manual handling risks.

✅ In April 2025, hospitals integrated automated plasma processing units for therapeutic development, combining AI monitoring, robotic fractionation, and real-time quality tracking to ensure high safety and efficiency.

Segment Covered in the Plasma-Derived Therapeutics Market:
By Product Type
The market is segmented into proteins (44%), coagulation factors (36%), and other plasma-derived products (20%). Proteins dominate due to their extensive use in treating immune deficiencies, chronic inflammatory disorders, and various therapeutic applications. Coagulation factors follow closely, driven by the prevalence of hemophilia and bleeding disorders requiring replacement therapy. Other plasma-derived products, including albumin and immunoglobulins, are witnessing steady adoption across clinical and homecare settings.

By Application
Based on application, the market includes hemophilia (38%), primary immunodeficiencies (27%), idiopathic thrombocytopenic purpura (ITP) (18%), and other applications (17%). Hemophilia leads owing to the chronic nature of the disorder, high treatment costs, and requirement for frequent replacement therapies. Primary immunodeficiencies are driving demand due to increasing awareness, early diagnosis, and long-term immunoglobulin therapy. ITP and other autoimmune disorders are emerging as significant areas for plasma-derived therapeutics use.

By End-User
The end-user segment comprises hospitals & specialty clinics (46%), homecare services (27%), ambulatory surgical centers (19%), and other end-users (8%). Hospitals and specialty clinics dominate due to in-hospital administration of plasma therapies and specialized monitoring requirements. Homecare services are expanding rapidly, supported by patient preference for home infusion therapies and advancements in safe administration protocols. Ambulatory surgical centers are also adopting plasma therapies for procedural and perioperative management.

Regional Analysis
North America - 42% Share
North America leads the market due to high prevalence of target diseases, well-established plasma collection infrastructure, robust reimbursement policies, and extensive R&D for plasma-derived therapies.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=plasma-derived-therapeutics-market

Europe - 28% Share
Europe holds a significant share, supported by a strong plasma donation network, increasing adoption of coagulation factor therapies, and rising prevalence of immunodeficiency disorders.

Asia Pacific - 18% Share
Asia Pacific is experiencing rapid growth owing to expanding healthcare infrastructure, increasing disease awareness, and growing plasma collection and processing facilities in countries such as China, India, and Japan.

Latin America - 7% Share
Latin America shows moderate growth, driven by improving healthcare access, increased hospital-based plasma therapy adoption, and rising awareness of hemophilia management.

Middle East & Africa - 5% Share
The Middle East & Africa market is emerging, fueled by developing healthcare infrastructure, increasing rare disease diagnosis, and gradual adoption of plasma-based therapies.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.